SLAMF1 and Miyoshi myopathy: SLAMF7 (CS1, CRACC, and CD319) is a surface signaling lymphocytic activation molecule (SLAM family) expressed on NK cells and PCs (both normal and malignant), while undetectable in other cells, which makes it a valid target for MM therapy (270, 271).